Drug developer Inovio Pharmaceuticals said on Friday the U.S. government had stopped funding for a late-stage study testing its COVID-19 vaccine candidate, due to the increasing availability of authorized shots in the country.
“This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products,” the U.S. Department of Defense told Inovio, according to a company statement.
The department will continue to fund an ongoing mid-stage study testing its vaccine candidate INO-4800, Inovio said.
The U.S. government last year launched the Operation Warp Speed program to p…
Keep on reading: US gov’t stops funding for late-stage study of Inovio’s COVID-19 vaccine